Physiogenex will be presenting a new DIO mouse study at the 9th Aging Research and Drug Discovery (ARDD) Meeting in Copenhagen, Denmark, August 30th-September 2nd, 2022.

The poster presentation, entitled “Metformin and time-restricted feeding combination improves non-alcoholic steatohepatitis, liver fibrosis and sarcopenia in diet-induced obese insulin resistant mice” will be delivered by Dr. François Briand, our Director of Research and Development, during the several poster sessions occuring during the meeting.

 Feel free to contact us if you wish to set-up an appointment with Dr. Briand during the 9th ARDD and/or discuss your drug development projects with us.

About us

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.